Porton Pharma Solutions Ltd., an end-to-end CDMO, has teamed up with Aojin Life Sciences (Yixing) Co., Ltd. to offer extensive CDMO services for Aojin in the CMC pharmaceutical research and GMP production of XDC conjugate drugs, focusing on dual IND filings in both China and the United States.
 
With nearly two decades of experience in providing integrated CDMO services, Porton has formed a multidisciplinary project team that connects drug substance and drug product technologies, blending expertise in both small and large molecules. This partnership ushers in a detailed and strategic collaboration between Porton and Aojin in the XDC conjugate drug field. Together, the companies are committed to advancing the global development of XDC conjugate drugs, ensuring early access to high-quality medicines for the public.